The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study

Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, Krüger H, Wahn U, Schaberg T, Schwehm M, Kochmann TF, et al. (2014)
BMC Infectious Diseases 14(1): 40.

Download
OA
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Volltext vorhanden für diesen Nachweis
Autor/in
; ; ; ; ; ; ; ; ; ; ;
Alle
Abstract / Bemerkung
Background Routine annual influenza vaccination is primarily recommended for all persons aged 60 and above and for people with underlying chronic conditions in Germany. Other countries have already adopted additional childhood influenza immunisation programmes. The objective of this study is to determine the potential epidemiological impact of implementing paediatric influenza vaccination using intranasally administered live-attenuated influenza vaccine (LAIV) in Germany. Methods A deterministic age-structured model is used to simulate the population-level impact of different vaccination strategies on the transmission dynamics of seasonal influenza in Germany. In our base-case analysis, we estimate the effects of adding a LAIV-based immunisation programme targeting children 2 to 17 years of age to the existing influenza vaccination policy. The data used in the model is based on published evidence complemented by expert opinion. Results In our model, additional vaccination of children 2 to 17 years of age with LAIV leads to the prevention of 23.9 million influenza infections and nearly 16 million symptomatic influenza cases within 10 years. This reduction in burden of disease is not restricted to children. About one third of all adult cases can indirectly be prevented by LAIV immunisation of children. Conclusions Our results demonstrate that vaccinating children 2–17 years of age is likely associated with a significant reduction in the burden of paediatric influenza. Furthermore, annual routine childhood vaccination against seasonal influenza is expected to decrease the incidence of influenza among adults and older people due to indirect effects of herd protection. In summary, our model provides data supporting the introduction of a paediatric influenza immunisation programme in Germany.
Erscheinungsjahr
Zeitschriftentitel
BMC Infectious Diseases
Band
14
Ausgabe
1
Seite(n)
40
ISSN
Finanzierungs-Informationen
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of Bielefeld University.
PUB-ID

Zitieren

Rose MA, Damm O, Greiner W, et al. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases. 2014;14(1):40.
Rose, M. A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J. G., Krüger, H., et al. (2014). The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases, 14(1), 40. doi:10.1186/1471-2334-14-40
Rose, M. A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J. G., Krüger, H., Wahn, U., Schaberg, T., Schwehm, M., et al. (2014). The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases 14, 40.
Rose, M.A., et al., 2014. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases, 14(1), p 40.
M.A. Rose, et al., “The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study”, BMC Infectious Diseases, vol. 14, 2014, pp. 40.
Rose, M.A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J.G., Krüger, H., Wahn, U., Schaberg, T., Schwehm, M., Kochmann, T.F., Eichner, M.: The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infectious Diseases. 14, 40 (2014).
Rose, Markus A, Damm, Oliver, Greiner, Wolfgang, Knuf, Markus, Wutzler, Peter, Liese, Johannes G, Krüger, Hagen, Wahn, Ulrich, Schaberg, Tom, Schwehm, Markus, Kochmann, Thomas F, and Eichner, Martin. “The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study”. BMC Infectious Diseases 14.1 (2014): 40.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
This Item is protected by copyright and/or related rights. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-09-06T09:18:21Z

14 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model.
Gerlier L, Lamotte M, Grenèche S, Lenne X, Carrat F, Weil-Olivier C, Damm O, Schwehm M, Eichner M., Appl Health Econ Health Policy 15(2), 2017
PMID: 27943165
Is the impact of childhood influenza vaccination less than expected: a transmission modelling study.
Weidemann F, Remschmidt C, Buda S, Buchholz U, Ultsch B, Wichmann O., BMC Infect Dis 17(1), 2017
PMID: 28399801
Direct and indirect effects of influenza vaccination.
Eichner M, Schwehm M, Eichner L, Gerlier L., BMC Infect Dis 17(1), 2017
PMID: 28441935
Variation in loss of immunity shapes influenza epidemics and the impact of vaccination.
Woolthuis RG, Wallinga J, van Boven M., BMC Infect Dis 17(1), 2017
PMID: 28927373
The 2016 Lifetime Immunization Schedule, approved by the Italian scientific societies: A new paradigm to promote vaccination at all ages.
Bonanni P, Chiamenti G, Conforti G, Maio T, Odone A, Russo R, Scotti S, Signorelli C, Villani A, Scientific Board of “Lifetime Immunization Schedule”., Hum Vaccin Immunother 13(11), 2017
PMID: 29048980
Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.
Smith KJ, Raviotta JM, DePasse JV, Brown ST, Shim E, Patricia Nowalk M, Zimmerman RK., Am J Prev Med 50(5), 2016
PMID: 26868283
Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles.
Gibson E, Begum N, Martinón-Torres F, Safadi MA, Sackeyfio A, Hackett J, Rajaram S., J Mark Access Health Policy 4(), 2016
PMID: 27429720
Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.
Gerlier L, Lamotte M, Dos Santos Mendes S, Damm O, Schwehm M, Eichner M., Paediatr Drugs 18(4), 2016
PMID: 27272706
Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.
Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Krüger H, Greiner W., Eur J Health Econ 16(5), 2015
PMID: 24859492
Modeling infectious disease dynamics in the complex landscape of global health.
Heesterbeek H, Anderson RM, Andreasen V, Bansal S, De Angelis D, Dye C, Eames KT, Edmunds WJ, Frost SD, Funk S, Hollingsworth TD, House T, Isham V, Klepac P, Lessler J, Lloyd-Smith JO, Metcalf CJ, Mollison D, Pellis L, Pulliam JR, Roberts MG, Viboud C, Isaac Newton Institute IDD Collaboration., Science 347(6227), 2015
PMID: 25766240
Live attenuated influenza vaccine tetravalent: a clinical review.
Bandell AR, Simões EA., Expert Rev Vaccines 14(7), 2015
PMID: 25864428

41 References

Daten bereitgestellt von Europe PubMed Central.

Clinical manifestations and socio-economic impact of influenza among healthy children in the community.
Esposito S, Cantarutti L, Molteni CG, Daleno C, Scala A, Tagliabue C, Pelucchi C, Giaquinto C, Principi N., J. Infect. 62(5), 2011
PMID: 21414357
High costs of influenza: Direct medical costs of influenza disease in young children.
Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA, Donauer S, Henderson D, Ambrose S, Kent D, Poehling K, Weinberg GA, Griffin MR, Hall CB, Finelli L, Bridges C, Staat MA; New Vaccine Surveillance Network (NVSN), Clay CA, Keckley E, Kent D, Whitehead N, Zhu Y, Albertin C, Lofthus G, Schnabel K, Florian V, Holloway M, Jamison L, Tabangin ME., Vaccine 28(31), 2010
PMID: 20576536
The underrecognized burden of influenza in young children.
Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, Bridges CB, Grijalva CG, Zhu Y, Bernstein DI, Herrera G, Erdman D, Hall CB, Seither R, Griffin MR; New Vaccine Surveillance Network., N. Engl. J. Med. 355(1), 2006
PMID: 16822994
Influenza-associated hospitalizations in the United States.
Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K., JAMA 292(11), 2004
PMID: 15367555
Influenza and the rates of hospitalization for respiratory disease among infants and young children.
Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, Black S, Shinefield H, Fukuda K., N. Engl. J. Med. 342(4), 2000
PMID: 10648764
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.
Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR., N. Engl. J. Med. 342(4), 2000
PMID: 10648763
The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB., Vaccine 25(27), 2007
PMID: 17544181
Seasonal influenza: the burden of disease in children.
Fraaij PL, Heikkinen T., Vaccine 29(43), 2011
PMID: 21820476
Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981.
Monto AS, Koopman JS, Longini IM Jr., Am. J. Epidemiol. 121(6), 1985
PMID: 4014174
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ; Centers for Disease Control and Prevention (CDC)., MMWR Recomm Rep 59(RR-8), 2010
PMID: 20689501
Differences in national influenza vaccination policies across the European union, Norway and Iceland 2008–2009
AUTHOR UNKNOWN, 2010

AUTHOR UNKNOWN, 2012
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children.
Usonis V, Anca I, Andre F, Chlibek R, Ivaskeviciene I, Mangarov A, Meszner Z, Prymula R, Simurka P, Tamm E, Tesovic G, Central European Vaccination Advisory Group ., BMC Infect. Dis. 10(), 2010
PMID: 20546586

AUTHOR UNKNOWN, 2012
Vaccines for preventing influenza in healthy children
AUTHOR UNKNOWN, 2012
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.
Osterholm MT, Kelley NS, Sommer A, Belongia EA., Lancet Infect Dis 12(1), 2011
PMID: 22032844
Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J., Vaccine 27(7), 2008
PMID: 19095024
Vaccines for preventing influenza in healthy children
AUTHOR UNKNOWN, 2008
Seasonal influenza in the United States, France, and Australia: transmission and prospects for control.
Chowell G, Miller MA, Viboud C., Epidemiol. Infect. 136(6), 2007
PMID: 17634159
Estimating the impact of childhood influenza vaccination programmes in England and Wales.
Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ., Vaccine 26(41), 2008
PMID: 18647634
Time lines of infection and disease in human influenza: a review of volunteer challenge studies.
Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ., Am. J. Epidemiol. 167(7), 2008
PMID: 18230677
Social contacts and mixing patterns relevant to the spread of infectious diseases.
Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska M, Edmunds WJ., PLoS Med. 5(3), 2008
PMID: 18366252

AUTHOR UNKNOWN, 2010
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network., Pediatr. Infect. Dis. J. 26(7), 2007
PMID: 17596805
Vaccines for preventing influenza in the elderly
AUTHOR UNKNOWN, 2010
Comparative efficacy of inactivated and live attenuated influenza vaccines.
Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC., N. Engl. J. Med. 361(13), 2009
PMID: 19776407
Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.
Blank PR, Schwenkglenks M, Szucs TD., J. Infect. 58(6), 2009
PMID: 19446340

AUTHOR UNKNOWN, 2009
Incidence of influenza and associated illness in children aged 0-19 years: a systematic review.
Bueving HJ, van der Wouden JC, Berger MY, Thomas S., Rev. Med. Virol. 15(6), 2005
PMID: 16178047

AUTHOR UNKNOWN, 2011

AUTHOR UNKNOWN, 2007
Economic evidence of influenza vaccination in children.
Savidan E, Chevat C, Marsh G., Health Policy 86(2-3), 2007
PMID: 18054109
Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.
Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, Crepey P., Hum Vaccin Immunother 8(3), 2012
PMID: 22330959
Oil-in-water emulsion adjuvant with influenza vaccine in young children.
Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R., N. Engl. J. Med. 365(15), 2011
PMID: 21995388

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 24450996
PubMed | Europe PMC

Suchen in

Google Scholar